Q32 Bio (NASDAQ:QTTB) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Q32 Bio (NASDAQ:QTTB) posted its quarterly earnings data on Tuesday. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.14, FiscalAI reports.

Q32 Bio Price Performance

Shares of QTTB traded down $0.05 during trading hours on Thursday, reaching $5.42. 154,779 shares of the company traded hands, compared to its average volume of 258,122. The company has a quick ratio of 4.85, a current ratio of 4.85 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $84.73 million, a PE ratio of 2.04 and a beta of -0.05. Q32 Bio has a fifty-two week low of $1.35 and a fifty-two week high of $8.05. The stock has a fifty day simple moving average of $5.88 and a 200 day simple moving average of $4.16.

Insider Activity at Q32 Bio

In related news, CEO Jodie Pope Morrison sold 9,896 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $4.51, for a total transaction of $44,630.96. Following the transaction, the chief executive officer directly owned 89,104 shares in the company, valued at approximately $401,859.04. This represents a 10.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 16,706 shares of company stock worth $75,344 over the last quarter. 40.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Q32 Bio

A number of large investors have recently modified their holdings of the company. Opaleye Management Inc. purchased a new position in shares of Q32 Bio in the 4th quarter worth about $708,000. Geode Capital Management LLC raised its holdings in shares of Q32 Bio by 19.9% in the 4th quarter. Geode Capital Management LLC now owns 106,113 shares of the company’s stock worth $352,000 after purchasing an additional 17,617 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Q32 Bio by 110.6% in the 4th quarter. Renaissance Technologies LLC now owns 99,600 shares of the company’s stock worth $331,000 after purchasing an additional 52,300 shares during the period. Jane Street Group LLC purchased a new position in shares of Q32 Bio in the 2nd quarter worth about $69,000. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Q32 Bio by 140.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 44,373 shares of the company’s stock worth $73,000 after purchasing an additional 25,953 shares during the period. 31.32% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Q32 Bio in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Q32 Bio in a research note on Friday, January 9th. Finally, Zacks Research raised Q32 Bio from a “hold” rating to a “strong-buy” rating in a report on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.00.

Q32 Bio News Summary

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright raised multiple near‑term and multi‑year EPS forecasts and reiterated a Buy rating with a $13 price target; the firm’s analyst J. Pantginis trimmed projected losses for Q2, Q3 and Q4 2026 (to ($0.48), ($0.50) and ($0.52) respectively) and improved FY2026–FY2028 and out‑year forecasts (FY2026 to ($2.04) from ($2.21); FY2027 to ($2.00); FY2028 to ($1.80); FY2029 to $0.20; FY2030 to $0.44). The revisions signal improved analyst confidence in the company’s longer‑term model and are a clear positive for valuation expectations. MarketBeat: Q32 Bio coverage
• Negative Sentiment: Q32 disclosed internal control challenges under Sarbanes‑Oxley (accounting & financial operations risk). Such SOX‑related weaknesses can lead to audit issues, higher compliance costs, delayed filings or restatements — all of which can pressure sentiment and create short‑term selling even when analyst models are improved. Investors should watch company filings and remediation plans closely. Regulatory Compliance Risks (TipRanks)

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.